lumacaftor vs Tezacaftor / ivacaftor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Cystic Fibrosis

Shared mechanism: CFTR · full Cystic Fibrosis pipeline

lumacaftor · Orkambi

Marketed by Vertex Pharmaceuticals

Approved in Cystic Fibrosissmall molecule
Reliable signal

NCT01807949 · Phase 3 · completed

The trial was randomized, double-blind, placebo-controlled, and included 563 participants. The hard clinical primary endpoint, change in percent-predicted FEV1, was significantly better with both lumacaftor/ivacaftor regimens than placebo: the treatment differences were 2.62 percentage points (p=0.0004) and 3.00 percentage points (p<0.0001).

No aligned efficacy figure on record for this race.

Tezacaftor / ivacaftor · Symdeko

Marketed by Vertex Pharmaceuticals

Approved in Cystic Fibrosissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT03587961 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Cystic Fibrosis

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

lumacaftor: registry results are on file for Cystic Fibrosis, but their comparison mappings are not yet available.

Tezacaftor / ivacaftor: registry results are on file for Cystic Fibrosis, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lumacaftor's landscape · Tezacaftor / ivacaftor's landscape